INCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Incyte Corp (INCY) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has shown strong financial growth in the latest quarter, the lack of significant positive catalysts, mixed analyst ratings, and potential long-term risks such as the Jakafi patent cliff in 2028 suggest a cautious approach. The technical indicators are neutral to slightly bullish, but they do not provide a compelling entry point for a long-term investor. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this stock for now is recommended.
The technical indicators show a mixed picture. The MACD is positive but contracting, RSI is neutral at 48.134, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 96.125, with key support at 93.31 and resistance at 98.941. The stock's recent price trend has been slightly bearish, with a regular market change of -1.83%.
Strong financial performance in Q4 2025, with revenue up 27.84% YoY, net income up 48.74% YoY, and EPS up 50.52% YoY.
SwingMax signal from 2026-03-31 with a 2.18% price increase since then.
Some analysts, like H.C. Wainwright, remain optimistic about post-Jakafi revenue catalysts.
Concerns over the Jakafi patent cliff in 2028, which analysts like Jefferies view as an existential risk.
Mixed analyst ratings with recent downgrades and reduced price targets (e.g., Jefferies and UBS).
Lack of recent news or event-driven catalysts to boost sentiment.
Stock trend analysis indicates a likelihood of short-term declines (-3.32% next week, -4.44% next month).
In Q4 2025, Incyte showed strong financial growth: revenue increased by 27.84% YoY to $1.506 billion, net income rose by 48.74% YoY to $299.28 million, and EPS grew by 50.52% YoY to 1.46. However, gross margin slightly declined by -0.57% YoY to 91.96%.
Analyst ratings are mixed. RBC Capital raised the price target to $95 but maintained a Sector Perform rating. Jefferies downgraded the stock to Hold with a reduced price target of $94, citing long-term risks. UBS also lowered its price target to $94. On the positive side, H.C. Wainwright initiated coverage with a Buy rating and a $135 price target, citing optimism about post-Jakafi revenue catalysts. Overall, there is no strong consensus among analysts.
